Zhou X, Moreira S, Restelli C, Wang H, Jahangiri S, Aryal S, Tsao E, Zhang P, Niu M, Kumar H, Balde Z, Vujovic A, Liu L, Wong N, Arruda A, Minden MD, Zhou Y, Ravi B, Qi J, Li C, Hope KJ, Lu R. Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models. Sci Transl Med. 2025 08 06; 17(810):eadn5400.